- Home
- SOWG vs BCDA Comparison
SOWG vs BCDA Comparison
Compare SOWG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- BCDA
- Stock Information
- Founded
- SOWG 2010
- BCDA N/A
- Country
- SOWG United States
- BCDA United States
- Employees
- SOWG N/A
- BCDA N/A
- Industry
- SOWG Packaged Foods
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- BCDA Health Care
- Exchange
- SOWG Nasdaq
- BCDA Nasdaq
- Market Cap
- SOWG 9.3M
- BCDA 10.1M
- IPO Year
- SOWG N/A
- BCDA N/A
- Fundamental
- Price
- SOWG $0.81
- BCDA $2.39
- Analyst Decision
- SOWG
- BCDA Strong Buy
- Analyst Count
- SOWG 0
- BCDA 1
- Target Price
- SOWG N/A
- BCDA $25.00
- AVG Volume (30 Days)
- SOWG 48.2K
- BCDA 230.7K
- Earning Date
- SOWG 08-13-2025
- BCDA 08-12-2025
- Dividend Yield
- SOWG N/A
- BCDA N/A
- EPS Growth
- SOWG N/A
- BCDA N/A
- EPS
- SOWG N/A
- BCDA N/A
- Revenue
- SOWG $23,063,113.00
- BCDA $3,000.00
- Revenue This Year
- SOWG $6.81
- BCDA N/A
- Revenue Next Year
- SOWG N/A
- BCDA N/A
- P/E Ratio
- SOWG N/A
- BCDA N/A
- Revenue Growth
- SOWG N/A
- BCDA N/A
- 52 Week Low
- SOWG $0.52
- BCDA $1.63
- 52 Week High
- SOWG $24.83
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- SOWG 50.98
- BCDA 58.67
- Support Level
- SOWG $0.78
- BCDA $1.98
- Resistance Level
- SOWG $0.86
- BCDA $2.45
- Average True Range (ATR)
- SOWG 0.05
- BCDA 0.17
- MACD
- SOWG -0.00
- BCDA 0.04
- Stochastic Oscillator
- SOWG 42.86
- BCDA 88.00
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).